Remedy Plan Therapeutics
PrivateLast Round
VC Round
May 13, 2025
Total Funding Raised
$22.91M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Remedy Plan Therapeutics is a biotechnology company developing a pipeline of novel, hyperbolic NAMPT inhibitors to treat a range of diseases including solid tumors, hematologic malignancies, obesity, and autoimmune disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Remedy Plan Therapeutics Comparables
Compare Remedy Plan Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| OncoTartis, Inc. | 90% | |
| Dracen Pharmaceuticals, Inc. | 77% | |
| Valerio Therapeutics | 74% |
Remedy Plan Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | May 13, 2025 | ||||
| Series A | Aug 1, 2023 | ||||
| Early Funding | Nov 20, 2018 | ||||
| Grant | Sep 20, 2018 | ||||
| Crowdfunding | Nov 6, 2015 |
Key People
Founding team and executive leadership
Remedy Plan Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Alexandria Venture Investments | VC Round |
| Schooner Capital | VC Round, Early Funding |
| Maryland Tech Council | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Grew 25% QoQ from 16 to 20 employees.
- Apr 8, 2026
Jotin Marango appointed as Chief Financial and Business Officer.
Recent news
Latest coverage and updates
- hiresSep 15, 2026
Remedy Plan hired Oleg Zernovak as Vice President, Clinical Development on Sep 15th '26.
Remedy Plan Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Remedy Plan Therapeutics's valuation, stock price, and market status.
Is Remedy Plan Therapeutics a public or private company?
Remedy Plan Therapeutics is a private company.
What is the current stock price of Remedy Plan Therapeutics?
Remedy Plan Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Remedy Plan Therapeutics worth (valuation)?
Valuation information for Remedy Plan Therapeutics is not publicly available.
Can I buy Remedy Plan Therapeutics stock?
Remedy Plan Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Remedy Plan Therapeutics's last funding round?
Remedy Plan Therapeutics's most recent funding round was Early Funding on May 13, 2025.
Who are the main investors in Remedy Plan Therapeutics?
Key investors in Remedy Plan Therapeutics include Alexandria Venture Investments, Schooner Capital, Maryland Tech Council.
Will Remedy Plan Therapeutics IPO soon?
No public IPO plans have been announced for Remedy Plan Therapeutics.
How can I track Remedy Plan Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Remedy Plan Therapeutics's secondary market activity and sign up for updates.